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Abstract
Purpose Many studies have proposed alternative designations
for lymph node (LN) status in colorectal cancer (CRC); how-
ever, knowledge of histopathological features in metastatic
lymph nodes (MLNs) is limited. This study investigated the
clinicopathological significance of poorly differentiated clus-
ters (PDCs) in MLNs.
Methods Slides from 159 patients with pathological Stage III
CRC were reviewed. Those with <12 dissected LNs (DLNs)
were ineligible. PDCs composed of ≥5 cancer cells lacking
full glandular formation and ≥10 PDCs under ×20 objective
lens were defined as positive, and the number of MLNs with
positive PDCs (MLNs-PDCs) was counted. Results were cor-
related with patient survival and comparisons made with other
indications of LN status.
Results The mean numbers of MLNs and MLNs-PDCs were
2.8 and 1.0, respectively, and were moderately and positively
correlated with each other. Univariate analysis identified cut-
offs of ≥5MLNs (86 vs. 55%, p=0.024), ≥2MLNs-PDCs (85
vs. 63 %, p=0.008), and ≥30 % LN ratio (85 vs. 44 %, p=
0.036) to indicate a positive LN status. However, no cutoff for
DLNs was obtained. MLNs-PDCs (≥2) were associated with
pT4 tumor (p=0.0035), open surgery (p=0.016), greater num-
ber of MLNs (p<0.0001), and positive-PDC primary tumor
(p<0.0001). In multivariate analysis, a prognostic model
incorporating ≥2 MLNs-PDCs provided the lowest Akaike
information criterion value; consequently, both pT4 tumors
(p<0.001) and ≥2 MLNs-PDCs (p=0.038) were revealed to
be significant prognosticators.
Conclusion Results showed that applying the number of
MLNs-PDCs could improve stratification in pStage III CRC
and may be a valuable candidate for LN status.
Keywords Colorectal cancer . Lymph node status . Poorly
differentiated clusters . Histopathological prognosticator
Introduction
The incidence of colorectal cancer (CRC) has increased grad-
ually over the decades in developed countries, and CRC now
is the third most-commonly diagnosed cancer [1]. Recent
progress in active cytotoxic chemotherapy regimens has con-
tributed to prolonged survival of patients with CRC [2, 3].
However, to reducemortality, there is a growing need for early
prediction of prognosis to further improve postoperative
interventions.
Since Dukes [4] reported the histopathological grading of
rectal cancer in 1937, accumulated evidence on CRC has con-
firmed the clinical importance of lymph node (LN) status. In
particular, the number of metastatic LNs (MLNs) has been
considered one of the most powerful predictors in CRC [5,
6] and guides the indication for adjuvant chemotherapy. On
the other hand, many researchers have proposed alternatives
to indicate LN status, including the total number of dissected
LNs (DLNs) [7–10], LN ratio (LNR) [11–15], and extramural
cancer deposits (EX) [16, 17]. However, to date, published
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More recently, a novel histological grading system using
poorly differentiated clusters (PDCs), which are composed of
≥5 cancer cells that present at the invasive front of the tumor
and lack full glandular formation, has been highlighted as a
histopathological prognosticator of CRC [18–20]. Presence of
PDCs was reported to be strongly positively correlated with
LN metastasis and poorer survival and, consequently, was
expected to provide a complementary approach to the conven-
tional pathological diagnostic process. However, despite in-
creasing evidence of PDCs as prognostic indicators, no previ-
ous studies have focused on PDCs in MLNs and their corre-
lation to PDCs in primary tumors. An understanding of the
histopathological behavior of PDCs in MLNs may provide
insights into the key process following LN metastasis.
Therefore, this study expanded upon the PDC concept of eval-
uation for histopathological features of MLNs and aimed to
clarify the clinicopathological importance of PDCs in MLNs
in comparison with previously reported LN status.
Patients and methods
Patients
This study examined data on patients with pathological Stage
III (pStage III) CRC who had undergone potentially curative
resection and systematic en bloc LN dissection at a single
institution from 2000 to 2012. Since laparoscopic surgery be-
came widespread during that period, cases in this study were
treated with either open or laparoscopic surgery. Following the
recommendation of the Union for International Cancer
Control (UICC) TNM classification [5] to eliminate possible
staging migration, patients with <12 DLNs were ineligible for
this study. In addition, although pelvic sidewall LN dissection,
which means removal of internal iliac and obturator LNs,
traditionally has been performed in Japan for locally advanced
lower rectal cancer [21, 22], patients on whom that dissection
method had been performed were excluded. Other exclusion
criteria for this retrospective cohort included (1) synchronous
or multiple cancers, (2) preoperative therapy (neoadjuvant
chemotherapy and endoscopic resection), (3) cancers related
to ulcerative colitis or Crohn’s disease, and (4) familial ade-
nomatous polyposis or hereditary non-polyposis colorectal
cancer. To be included for analysis, after resection, patients
were required to have follow-up surveillance at 3-month in-
tervals for 1 year, then every 6 months for 3 years, and yearly
thereafter. Prior to the study’s initiation, approval to use pa-
tient data for research purposes was obtained at the institution.
Specimens
Within an hour after resection, all regional LNs were manually
retrieved from the en bloc resected specimens after visual
observation and palpation. The process of sectioning speci-
mens after formalin fixation was performed according to
Japanese guidelines [6]. In particular, larger retrieved LNs
were longitudinally cut through the hilus, and smaller ones
were embedded in paraffin whole. Sections 3 μm thick were
cut from paraffin-embedded specimens and mounted onto
glass slides. After deparaffinization, slides were stained with
conventional hematoxylin and eosin according to the standard
procedure.
Histopathological evaluation
According to criteria set previously [18, 19], PDCs were de-
fined as cancer clusters lacking full glandular formation and
composed of ≥5 cancer cells, which are commonly observed
at the invasive front of the tumor. All slides were reviewed
pathologically, with special attention paid to the presence of
PDCs, and ≥10 PDCs under a microscopic field with a ×20
objective lens were defined as positive PDCs. Our previous
study [23] reported representative slides of PDCs in primary
tumors. In the present study, PDCs in primary tumors were
evaluated at the invasive front, whereas PDCs in MLNs were
evaluated where they were observed most commonly (Fig. 1),
and the number of MLNs with positive PDCs (MLNs-PDCs)
was counted.
In addition to a pathologically proven number of DLNs, the
LNR, defined as the number of MLNs divided by the number
of DLNs, was assessed as LN status. For EX lacking residual
LN structure, the study adopted the definition in Japanese
guidelines [6]; consequently, EX were comprehensively con-
sidered as MLNs. However, tumor nodules that might be re-
lated to an isolated cancer focus in the lymphovascular vessels
or perineural space were not considered as MLNs [16].
In addition, other pathological variables were obtained by
observing slides. All slides were evaluated by a trained pathol-
ogist specializing in gastrointestinal pathology and blinded to
the patients’ outcome.
Statistical analysis
Overall survival (OS) curves were drawn by the Kaplan-Meier
method, and comparisons between groups were performed
using the log-rank test, with the length of the follow-up period
being truncated at 5 years. In addition, the cutoff for each LN
status was optimized by maximizing the significance.
Correlation analysis was performed using the Spearman rank
correlation coefficient. Multivariate Cox proportional hazard
regression analysis was developed using stepwise regression
among representative variables, and the hazard radio (HR) and
95 % confidence interval (CI) for each variable were calculat-
ed. Furthermore, adequacy of the parametric model was
assessed by the Akaike information criterion (AIC) [24] to
estimate the most fitting model with the smallest information
284 Int J Colorectal Dis (2016) 31:283–290
loss and to compare models consisting of various combina-
tions of variables. Differences were considered statistically
significant at the p<0.05 level.
All statistical calculations were performed by EZR statisti-
cal software (Saitama Medical Center, Jichi Medical
University, Saitama, Japan) [25], which is a graphical user
interface for R (The R Foundation for Statistical Computing,
Vienna, Austria).
Results
The study enrolled 159 patients. As Table 1 shows, 111 tu-
mors (70 %) were colonic and 48 (30 %) were rectal. Most
patients had pT3 or pT4 lesions (90 %), and half had positive-
PDC primary tumors (50 %). One hundred seven patients
(69 %) received adjuvant chemotherapy consisting mainly of
5-fluorouracil (5-FU); however, 52 (31%) did not. At the time
of this study, the median follow-up was 48.5 months and the
5-year OS rate of this cohort was 79 %. On average, there
were 22.7 DLNs; of those, 2.8 MLNs and 1.0 MLN-PDCs
were detected pathologically. No difference was found be-
tween open and laparoscopic surgery in the number of
DLNs and MLNs (mean DLNs, 23.5 vs. 21.7, respectively;
mean MLNs, 3.1 vs. 2.6, respectively). The study found a
moderately positive correlation between the number of
MLNs-PDCs and number of MLNs and a slight correlation
between the number of MLNs with positive and negative
PDCs. Figure 2 shows scatter plots for the number of
MLNs-PDCs and MLNs.
Based on the Kaplan-Meier survival method, univariate
analysis identified a cutoff of 5 MLNs (86 vs. 55 %, p=
0.024), 2 MLNs-PDCs (85 vs. 63 %, p=0.008), and LNR of
30 % (85 vs. 44 %, p=0.036) as the statistically reliable strat-
ifications to discriminate patient survival (Fig. 3). Given this,
we decided upon ≥5 MLNs, ≥2 MLNs-PDCs, and ≥30 %
LNR to indicate positive LN status for subsequent analysis.
On the other hand, when the study analyzed from 13 to 91
Fig. 1 Representative examples of metastatic lymph nodes with positive
PDCs under low-power view (a) and under the view of ×20 objective lens
using hematoxylin and eosin stain (b). PDCs (>10) are observed
(arrowheads). The scale bar indicates 200 μm
Table 1 Patients and tumor characteristics (n=159)
Variables









Tumor size (mm) [mean (range, SD)] 47 (10–110, 19.4)





PDCs in primary tumor [n (%)]
Positive 80 (50)
Negative 79 (50)
DLNs [mean (range, SD)] 22.7 (12–91, 11.7)
MLNs [mean (range, SD)] 2.8 (1–18, 2.7)
LNR [median (IQR)] 0.09 (0.06–0.17)
MLNs-PDCs [mean (range, SD)] 1.0 (0–8, 1.4)
Operative approach [n (%)]
Open 83 (52)
Laparoscopic 76 (48)
Adjuvant chemotherapy [n (%)]
With 107 (69)
Without 52 (31)
PDCs poorly differentiated clusters,DLNs dissected lymph nodes,MLNs
metastatic lymph nodes, LNR lymph node ratio, MLNs-PDCs metastatic
lymph nodes with positive PDCs
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DLNs, a statistical threshold for 5-year OS was not ob-
tained. Table 2 shows comparison of clinicopathological
variables between patients with ≥2 MLNs-PDCs and <2.
MLNs-PDCs (≥2) were associated with pT4 tumors (p=
0.0035), open surgery (p=0.016), a greater number of
MLNs (p<0.0001), and a positive-PDC primary tumor
(p<0.0001). When the combination of PDC status in pri-
mary tumors and the number of MLNs-PDCs was exam-
ined, there were only two (3 %) negative-PDC primary
tumors among those with ≥2 MLNs-PDCs. In contrast,
of patients with <2 MLNs-PDCs, 53 (41 %) had
positive-PDC primary tumors and 77 (59 %) had
negative-PDC ones.
Fig. 2 a Scatter plots for the number of MLNs-PDCs and the number of
MLNs. The graph shows a moderate correlation between the two
(Spearman rank correlation coefficient 0.405, p<0.0001). b Scatter plots
for the number of MLNs with positive and negative PDCs. Little
correlation is found between the two (Spearman rank correlation
coefficient 0.145, p=0.068)
Fig. 3 Comparison of survival curves for each lymph node status
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Furthermore, in the subgroup analysis for the 128 patients
with <5MLNs, the 5-year OS rates of the patients with ≥2 (n=
14) and <2 MLNs-PDCs (n=114) were 68 and 88 % (p=
0.037). In contrast, in subgroup analysis for the 26 patients
with ≥5 MLNs, there was no significant difference in the 5-
year OS rates between the patients with ≥2 and <2 MLNs-
PDCs (59 and 53 %; p=0.70). In addition, in another sub-
group analysis for patients who received adjuvant chemother-
apy and those who did not, 5-year OS rates of patients with
and without chemotherapy were 67 vs. 64 % in ≥2 MLNs-
PDCs and 87 vs. 82 % in <2 MLNs-PDCs, and no significant
difference was found between the groups.
As Table 3 shows, among the representative clinicopatho-
logical variables, including LN status, the following five var-
iables were identified using the AIC in multivariate analysis:
tumor location (rectum vs. colon), number of MLNs-PDCs
(≥2 vs. <2), sex (female vs. male), tumor size (≥50 vs.
<50 mm), and T status (pT4 vs. pT1–3). Consequently, both
pT4 tumors (HR=3.54, p<0.001) and ≥2 MLNs-PDCs (HR=
2.50, p=0.038) were revealed as significant prognosticators
for 5-year OS. Finally, the prognostic model incorporating
≥2 MLNs-PDCs had higher accuracy with lower AIC value
(AIC=230.08) than models incorporating other indicators of
LN status, such as ≥5 MLNs (AIC=231.21) or ≥30 % LNR
(AIC=231.77).
Discussion
The present study examined prognostic properties of the num-
ber of MLNs-PDCs in a retrospective cohort comprising 159
patients with pStage III CRC. Since the clinical importance of
PDCs in primary tumors has been clarified successfully [18,
19, 23, 26], criteria modified by the authors was applied to
investigate histopathological features inMLNs. To our knowl-
edge, this is the first study to highlight the histopathological
features of PDCs in MLNs as a candidate for a new LN status.
Results showed that ≥2 MLNs-PDCs were associated
closely with PDC-positive primary tumors, implying that
PDC status in metastatic sites frequently could parallel that
in primary tumors. On the other hand, this study found that
some PDC-positive tumors were not accompanied by PDC-
positive MLNs. Using similar approaches, Takahashi et al.
[27] found histopathological heterogeneity between primary
Table 2 Comparison of variables







Age (year) [mean (range, SD)] 66.5 (21–95, 14.0) 65.0 (21–85, 11.4)
Sex [n (%)]
Male 15 (10) 61 (38) 0.64
Female 14 (9) 69 (43)
Tumor location [n (%)]
Colon 0.11
Cecum-transverse 12 (8) 39 (25)
Descending-sigmoid 6 (4) 54 (34)
Rectum 11 (7) 37 (24)
Tumor size (mm) [mean (range, SD)] 54 (20–110, 24.3) 45 (20–110, 18.0) 0.16
T status [n (%)]
pT1 0 (0) 1 (1) 0.0035 (T1–3 vs. T4)
pT2 0 (0) 15 (9)
pT3 16 (10) 89 (56)
pT4 13 (8) 25 (16)
PDCs in primary tumor [n (%)]
Positive 27 (17) 53 (33) <0.0001
Negative 2 (1) 77 (48)
DLNs [mean (range, SD)] 23.9 (12–85, 14.4) 22.4 (12–91, 11.1) 0.68
MLNs [mean (range, SD)] 5.51 (2–18, 3.55) 2.19 (1–13, 1.95) <0.0001
LNR [median (IQR)] 0.24 (0.13–0.37) 0.08 (0.05–0.14) <0.0001
Operative approach [n (%)]
Open 21 (13) 62 (39) 0.016
Laparoscopic 8 (5) 68 (43)
Adjuvant chemotherapy [n (%)]
With 22 (14) 85 (53) 0.28
Without 7 (4) 45 (28)
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tumors and their synchronous MLNs in CRC patients.
Furthermore, it is worth mentioning that Mori et al. [28] dem-
onstrated that histopathological heterogeneity between prima-
ry tumors and their synchronous MLNs was associated with
poorer survival even after adjuvant chemotherapy was
administered. However, in the subgroup of this study that
examined the effect of adjuvant chemotherapy, no signif-
icant difference was found between patients with ≥2 and
<2 MLNs-PDCs. It is possible that this inconsistent re-
sult is due to the small sample size. Another possible
explanation is that there was no control over the chemo-
therapy regimens given to patients, since those regimens
progressed from single-dose 5-FU to combinations using
5-FU and oxaliplatin or irinotecan or both [2, 3] over the
period of this study. In this context, additional prospec-
tive studies using larger sample sizes would confirm our
results.
The most important finding of this study was that ≥2
MLNs-PDCs were associated strongly with a poorer 5-year
OS. Although the number of MLNs-PDCs was correlated
moderately positively with the number of MLNs, the number
of MLNs-PDCs could provide the highest degree of discrim-
ination regarding patient survival compared with the number
of MLNs and other measures of LN status that are based on
the theory of AIC. These findings suggest that the number of
MLNs-PDCs could provide more precise information on po-
tential tumor aggressiveness at the metastatic site.
Furthermore, this study assessed the subgroups of patients
with <5 MLNs, and there was significant difference in the 5-
year OS rates between patients with ≥2 and <2 MLNs-PDCs.
Consequently, this outcome suggests that MLNs-PDCs might
contribute to further survival stratification, especially for CRC
patients with <5 MLNs. Interestingly, Komuta et al. [29] and
Fujii et al. [30] reported the Bextracapsular invasion^ of
MLNs, which was highly indicative of tumor aggressiveness
at the metastatic site. This concept seems to be similar to that
of PDCs in MLNs in our study. Likewise, Ueno et al. [16]
described EX that exhibited active, invasive lesions as
Baggressive EX,^ which was associated with a dramatically
worse prognosis. Since evaluation criteria in this study
allowed EX to be comprehensively considered as MLNs, it
is possible that MLNs with positive PDCs included some
aggressive EX.
This study has some potential limitations. First, the 5-year
OS rate of 79 % in patients with pStage III CRC in this cohort
seems to be relatively better than that estimated in studies with
larger populations [2, 3]. The reason for this remains unclear.
Second, the exceedingly high hazard ratio may be a product of
the single-institution experience and the relatively small sam-
ple size in this study. Another question is why ≥2 MLNs-
PDCs were related to open surgery (p=0.016) even though
the number of DLNs and MLNs did not differ statistically
between open and laparoscopic surgery. One possible ex-
planation is surgeons’ preoperative choices, in which cases
with clinically diagnosed T4 tumors were treated by open
surgery. In addition, although cumulative evidence has
confirmed a larger number of MLNs as a strong prognos-
ticator of CRC, cutoff thresholds for some LN statuses
addressed in this study remain under intense discussion.
With respect to the cutoff threshold of LNR, Yuan et al.
[13] defined it as 33 %, Gleisner et al. [14] as 50 %, and
Madbouly et al. [15] as 38 %. Although consensus has
not been reached regarding this cutoff, they agreed that a
higher LNR was an adverse prognosticator. The cutoff of
30 % in this study seems to be comparable to aforemen-
tioned data. In contrast, similar to the experience of
Kotake et al. [10], we did not identify a statistically reli-
able cutoff for the number of DLNs. Although existing
guidelines [5, 6] recommend that ≥12 DLNs be examined
to eliminate possible staging migration, some researchers
Table 3 Univariate and
multivariate survival analysis of
histological valuables
Variables Univariatea Multivariateb
p Value HR 95 % CI p Value
Age (year) (≥65 vs. <65) 0.29 – – –
Sex (female vs. male) 0.23 2.15 0.88–5.24 0.093
Tumor location (rectum vs. colon) 0.072 2.23 0.98–5.05 0.055
Tumor size (≥50 vs. <50 mm) 0.70 2.20 0.89–5.45 0.089
T status (T4 vs. T1–3) 0.032 3.54 1.37–9.14 0.009
MLNs (≥5 vs. <5) 0.024 – – –
LNR (≥30 vs. <30 %) 0.004 – – –
MLNs-PDCs (≥2 vs. <2) 0.008 2.50 1.09–5.74 0.031
Adjuvant chemotherapy (without vs. with) 0.31 – – –
a Kaplan and Meier method, and statistical significance was determined by log-rank test
bMultivariate survival analysis was performed using Cox’s proportional hazard model
HR hazard ratio, CI confidence interval
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claim that there is no minimum number of DLNs that
would enhance the accuracy of staging pStage III CRC
[8, 9]. Therefore, this issue merits further discussion.
Conclusion
The PDCs in MLNs were closely associated with that in pri-
mary tumors. The number of MLNs-PDCs could exert an
effect on survival and provide more concise information to
improve stratification in pStage III CRC and, consequently,
could be a candidate for a new, alternative LN status. This
study demonstrated the need for special observation of
PDCs in MLNs during pathological diagnosis.
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